公开(公告)号：US20170233339A1

公开(公告)日：2017-08-17

申请号：US15518782

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro BANNO ,  Masahiro KAMAURA ,  Takahiko TANIGUCHI ,  Kazuaki TAKAMI ,  Koichiro FUKUDA ,  Shigekazu SASAKI

IPC: C07D207/08

CPC classification number: C07D207/08 ,  A61K31/40 ,  A61K31/401 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20240390508A1

公开(公告)日：2024-11-28

申请号：US18685457

申请日：2022-08-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Takatoshi YOGO ,  Hideyuki SUGIYAMA ,  Kenichi MIYATA ,  Hiroyuki TAKADA ,  Masato YOSHIDA ,  Ryosuke TOKUNOH ,  Yasuo NAKAGAWA ,  Masato NIWA ,  Shigekazu SASAKI ,  Masaki OHUCHI ,  Naoki SAWAI ,  Masatoshi TAKUWA ,  Yujiro UCHINO ,  Yoko KANEMATSU ,  Koichiro FUKUDA ,  Takanori YOKOTO ,  Tetsuya NAGATA ,  Hiroki YAMADA

IPC: A61K47/64 ,  A61K38/17 ,  A61K48/00 ,  C12N15/113

Abstract: The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.

公开(公告)号：US20170129887A1

公开(公告)日：2017-05-11

申请号：US15264213

申请日：2016-09-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi MIKAMI ,  Shinji NAKAMURA ,  Tomoko ASHIZAWA ,  Shigekazu SASAKI ,  Takahiko TANIGUCHI ,  Izumi NOMURA ,  Masanori KAWASAKI

IPC: C07D471/04 ,  A61K31/555 ,  A61K31/498 ,  A61K9/20 ,  C07F7/18

CPC classification number: C07D471/04 ,  A61K9/20 ,  A61K31/498 ,  A61K31/555 ,  C07D519/00 ,  C07F7/1804

Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like.The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20180237404A1

公开(公告)日：2018-08-23

申请号：US15517227

申请日：2015-10-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yoshihiro BANNO ,  Masahiro KAMAURA ,  Kazuaki TAKAMI ,  Koichiro FUKUDA ,  Shigekazu SASAKI

IPC: C07D263/46 ,  C07D213/70 ,  C07D231/12 ,  A61P27/02

CPC classification number: C07D263/46 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4418 ,  A61K31/505 ,  A61P27/02 ,  C07D213/65 ,  C07D213/70 ,  C07D231/12 ,  C07D231/22 ,  C07D239/34 ,  C07D263/38 ,  C07K14/47 ,  C12N15/09

Abstract: Provided is a heterocyclic compound having a superior RBP4-lowering action and useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4. A compound represented by the formula (I): wherein each symbol is as defined in the Description, or a salt thereof has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of a disease or symptom mediated by an increase in RBP4 or retinol supplied by RBP4.

公开(公告)号：US20170349605A1

公开(公告)日：2017-12-07

申请号：US15539607

申请日：2015-12-24

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Minoru SASAKI ,  Fumiaki KIKUCHI ,  Zenichi IKEDA ,  Keiko KAKEGAWA ,  Yoichi NISHIKAWA ,  Shigekazu SASAKI ,  Koichiro FUKUDA ,  Kazuaki TAKAMI ,  Yoshihiro BANNO ,  Masahiro KAMAURA

IPC: C07D495/04 ,  C07D491/044 ,  C07D413/06 ,  C07D323/00 ,  C07D313/00 ,  C07D321/12 ,  C07D321/00 ,  C07D313/20 ,  C07D493/04 ,  C07D405/06

CPC classification number: C07D495/04 ,  A61K31/365 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/422 ,  A61K31/662 ,  C07D313/00 ,  C07D313/20 ,  C07D321/00 ,  C07D321/12 ,  C07D323/00 ,  C07D405/06 ,  C07D409/12 ,  C07D413/06 ,  C07D491/044 ,  C07D493/04 ,  C07F9/655

Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].